NCT02627963 2023-07-18A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)AVEO Pharmaceuticals, Inc.Phase 3 Completed350 enrolled 14 charts 1 FDA